Publikationsliste

Manuskripte:

Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, van Etten RA, Dörken B, le Coutre P. Radiosensitization of a Human Glioblastoma Cell Line by Imatinib Mesylate Through Inhibition of Platelet-Derived Growth Factor Receptor.

Blood Cells Mol Dis. 2005 Mar-Apr; 34(2): 181-5

Na IK, Kreuzer KA, Lupberger J, Dörken B, le Coutre P. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl+ CML.
Leuk Res. 2005 Mar; 29(3): 343-5

Kreuzer KA*, le Coutre P*, Landt O*, Na IK, Schwarz M, Schultheis K, Hochhaus A, Dörken B. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Ann Hematol. 2003 May; 82(5):284-9. Epub 2003 Apr 12

le Coutre P*, Kreuzer KA*, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome.

Am J Hematol 2003; 73: 249-255

le Coutre P*, Kreuzer KA*, Na IK, Lupberger J, Holdhoff M, Appelt C, Schwarz M, Müller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA. Determination of alpha-1 acid glycoprotein in patients with Ph plus chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

Blood Cells Mol Dis 2002; 28: 75-85

Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P, Schmidt CA. Fluorescent 5 '-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.

Br J Haematol 2001; 114:313-318

* gleichberechtigte Autoren

Poster:

Honczarenko M, Glodek AM, Swierkowski M, Na IK, Silberstein, LE. Developmental stage specific shift in responsiveness to CXC/CC chemokines during B cell development in human bone marrow. Novel role of MIP-3b/CCR7 in early progenitor B cell development.

Blood 2003; 102: 162 (45th Annual Meeting of the American Society of Hematology, San Diego, USA)

Kreuzer KA, le Coutre P, Na IK, Schwarz M, Schultheis K, Landt O, Hochhaus A and Dörken B. Early and sensitive detection of primary and secondary resistance to imatinib mesylate in chronic myelogenous leukaemia by a novel PNA based PCR clamping assay.

Onkologie 2002; 25 (Suppl.4)

Kreuzer KA, le Coutre P, Landt O, Na IK, Schwarz M, Holdhoff M, Laurisch K, Hochhaus A, Dörken B. De novo and acquired resistance to imatinib in chronic myeloid leukemia as assessed by abl mutations detected through a highly sensitive PNA-clamped hybridization probe assay.Blood 2002; 100: 1232 (44th Annual Meeting of the American Society of Hematology, Philadelphia, USA)

Holdhoff M, le Coutre P, Kreuzer KA, Appelt C, Jordan R, Scholz R, Na IK, Schwarz M, Lupberger J and Schmidt CA. In vitro effects of the combined administration of Tyrosine Kinase inhibitor STI571 (Imatinib, Glivec) and ionizing radiation on a human glioblastoma cell line: potential use as a radiosensitizer? Strahlenther. Onkol. 2002; 178 (Suppl.1): 48

le Coutre P, Kreuzer KA, Holdhoff M, Appelt C, Jordan A, Scholz R, Schwarz M, Na IK, Lupberger J, Schmidt CA. Effects of the tyrosine kinase inhibitor STI571 and ionizing radiation on a human glioblastoma cell line: Potential use as a radiosensitizer. Blood 2001; 98: 4408

(43rd Annual Meeting of the American Society of Hematology, Orlando, USA)

Kreuzer KA, Le Coutre P, Na IK, Lupberger J, Schwarz M, Holdhoff M, Gschaidmeier H, Schmidt CA. Therapeutic response in 37 chronic phase patients under treatment with STI571 as assessed by hematological and cytogenetic parameters as well as by quantitative real time PCR for bcr-abl mRNA transcripts.

Blood 2001; 98: 4774 (43rd Annual Meeting of the American Society of Hematology, Orlando, USA)

le Coutre P, Kreuzer KA, Lupberger J, Na IK, Holdhoff M, Appelt C, Schwarz M, Müller C, Gambacorti-Passerini C, Platzbecker U, Ehninger G, Schmidt CA. Alpha-1 acid glycoprotein levels in patients with chronic myeloid leukemia during treatment with STI571: Determination of plasma protein and mRNA levels during the first 13 weeks of therapy.

Blood 2001; 98: 1304 (43rd Annual Meeting of the American Society of Hematology, Orlando, USA)

Kreuzer KA, le Coutre P, Na IK, Lupberger J, Appelt C, Saborowski A, Schmidt CA. Wilms Tumor gene (WT1) mRNA quantitation by real time fluorescence RT-PCR is a powerful tool to monitor the disease course of acute myelogenous and lymphatic as well as chronic myelogenous leukemia.

Bone Marrow Transpl 2001; 27: S29 (27th Annual Meeting of the European Group for Blood and Marrow Transplantation, Maastricht, Netherlands)

Kreuzer KA, le Coutre P, Saborowski A, Lupberger J, Appelt C, Na IK, Bohn A, Schmidt CA. In vitro treatment of chronic myeloid leukemia cells with STI571 leads to an equal reduction of Wilms tumor gene (WT1) and bcr-abl mRNA transcripts. Blood 2000; 96: 423

(42nd Annual Meeting of the American Society of Hematology, New Orleans, USA)


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
07.06.2005